A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with pseudomonas aeruginosa lung infection

Forest Laboratories UK Ltd0 个研究点目标入组 360 人开始时间: 2004年12月6日最近更新: 2012年3月19日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 360

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•a) Male or female aged 6 years and above.
•b) Patients who are receiving Tobi® in a cycle of 28 days active therapy followed by 28 days of rest from treatment.
•c) Patients who, on the first day of trial medication administration (Visit 1), will have received a minimum of 2 Tobi® on/off cycles immediately prior to randomisation.
•d) If the patient is female and post-menarche/ pre-menopausal and heterosexually active, the patient must be using adequate effective contraceptive methods.
•e) Patients are required to be non-smokers or a past smoker who has not smoked within the past 12 months prior to the first day of trial medication administration (Visit 1).
•f) Each patient or parent/ guardian must be capable of reading and understanding informed consent (assent for those under the legal contractual age of consent) and the clinical trial information leaflet.
•g) Each patient or parent/ guardian must have granted his or her written informed consent (with assent from those under the legal contractual age of consent) before any trial procedure is carried out.
•h) Patient must have a documented diagnosis of CF from a specialist CF Unit (genotype and/ or positive sweat tests).
•i) Current CF condition must be clinically stable in the investigator’s opinion i.e. there must be no evidence of a current acute respiratory exacerbation at Visit 1. A diagnosis of an acute respiratory exacerbation (which may not necessarily precipitate the need for immediate hospitalisation) is defined as the presence of at least four of the following:
•(i)Change in appearance of sputum (i.e. increased purulence or volume).
•(ii) Increased productive cough, dyspnoea or respiratory rate.
•(iii) Progressive physical findings (crackles, rhonchi and air exchange) on chest auscultation.
•(iv) New (infiltrates) intrusion on chest X-ray.
•(v) Lassitude and decreased exercise tolerance.
•(vi) Fever (=38oC).
•(vii) Deterioration of 10% of highest FEV1 score obtained in the last 6 months.
•(viii) Decreased appetite.
•(ix) Emergence of new pathogen in sputum i.e. a pathogen that causes clinical disease.
•j) FEV1 must be at least 25% but no more than 75% of predicted value (see Appendix VI for predicted values).
•k) Patients with Pseudomonas aeruginosa infection (including colonisation), defined as either:
•(i) = 50% samples (minimum of 3 samples: sputum samples or throat swabs) positive for PA over the previous 12 months prior to the first day of trial medication administration (Visit 1) OR
•(ii) two samples (sputum samples or throat swabs) positive for PA over the previous 6 months prior to the first day of trial medication administration (Visit 1).
•l) Patient’s lung function must be clinically stable (investigator’s decision) after completing i.v. therapy (elective or treatment for exacerbation) at Visit 1 prior to randomisation.
•m) Patient’s who, on the first day of trial medication administration (Visit 1), will have had at least 28 days but no more than 35 days off TOBI®.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•a) Evidence of an acute respiratory exacerbation on the first day of trial medication administration (Visit 1).
•b) Known sensitivity (or previous intolerance) to colistimethate sodium or ß2 agonists.
•c) Administration of any investigational drug within 28 days prior to first trial medication administration (Visit 1).
•d) Patients who have received treatment which has permanently reduced Pseudomonas aeruginosa infection status will not be included (e.g. effective anti-pseudomonal vaccination and gene therapy).
•e) Existence of any pre-study medical conditions which, in the judgement of the investigator, warrants exclusion from the study.
•f) Patients who are pregnant or breast-feeding, or who plan to become pregnant during the study period.
•g) Inability to communicate or co-operate with the investigator due to language problems, poor mental development or impaired cerebral function.
•h) Objection by the patient’s usual CF care-giver to their participation in the study.
•i) Inability to comply with any of the study procedures or the study regimen (including inability to use study devices i.e. Turbospin® device or PARI LC Plus® nebuliser for duration of the trial).
•j) Laboratory parameters falling outside the expected normal ranges for CF (Investigator decision).
•k) Children who in the opinion of the investigator would not be reliable in handling the devices.
•l) Patients who are or will be receiving an elective course of intravenous antibiotic therapy on the day of anticipated first administration of trial medication (i.e. Visit 1).
•m) Patients who, on the first day of trial medication administration (Visit 1), will have had less than 28 days or more than 35 days off Tobi® or less than 28 days off inhaled colistin.
•n) Patients who, on the first day of trial medication administration (Visit 1), are receiving anti-pseudomonal agents specifically for the treatment of an exacerbation or pre-scheduled prophylactic courses of oral antibiotics. [Long term use of antibiotics (e.g. ciprofloxacin) for prophylaxis or anti-inflammatories (e.g. azithromycin) is permitted, provided the regimen has been used for at least 28 days and is planned to continue throughout the study.]
•o) Patients who need to receive another anti-pseudomonal agent as part of their standard care during the off-cycle of Tobi®. [Long term use of antibiotics (e.g. ciprofloxacin) for prophylaxis or anti-inflammatories (e.g. azithromycin) is permitted, provided the regimen has been used for at least 28 days and is planned to continue throughout the study.]
•p) Patients who are infected/ colonised with Burkholderia cepacia.
•q) Patients who are complicated by symptoms related to allergic bronchopulmonary aspergillosis (ABPA).
•r) Patients who are awaiting heart-lung or lung transplantation, where the transplant is likely to take place within 6 months of the first day of trial medication administration (i.e. Visit 1).
•s) Patient’s lung function not clinically stable (investigator’s decision) after completing i.v. therapy (elective or treatment for exacerbation) at Visit 1 prior to randomisation.

研究者

发起方

Forest Laboratories UK Ltd

相似试验

进行中（未招募）

不适用

A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with pseudomonas aeruginosa lung infectioPseudomonas aeruginosa (PA) infection in patients with cystic fibrosis.

EUCTR2004-003675-36-BEForest Laboratories UK Ltd360

进行中（未招募）

不适用

EUCTR2004-003675-36-ATForest Laboratories UK Ltd360

进行中（未招募）

不适用

A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - Once-daily Darunavir In treatment-experieNced patients (ODIN)HIV-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infection

EUCTR2007-001939-61-DETibotec Pharmaceuticals Ltd.612

进行中（未招募）

不适用

EUCTR2007-001939-61-HUTibotec Pharmaceuticals Ltd.612

进行中（未招募）

不适用

EUCTR2007-001939-61-ATTibotec Pharmaceuticals Ltd.612